Compare Futu Holdings Ltd (FUTU) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Futu Holdings Ltd vs GSK plc — how do they compare? Futu Holdings Ltd trades at $113.71 (market cap $15.25B), while GSK plc trades at $46.5 (market cap $91.88B). The key difference: GSK plc is far larger — about 6× Futu Holdings Ltd's market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold Futu Holdings Ltd for 34 Days and GSK plc for 93 Days on average.
| FUTU | GSK | |
|---|---|---|
Market Cap | $15.25B | $91.88B |
Volume | 812,567 | 7,730,529 |
Sector | Financials | Health |
52-Week High | $199.04 | $61.18 |
52-Week Low | $89.76 | $43.24 |
Typical Hold Time | 34 Days | 93 Days |
Enterprise Value | $15.59B | $111.88B |
Dividend Yield | 2.39% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Futu Holdings trades at $108.76, down 0.84% today, with a bearish technical signal despite strong fundamentals. The company reported robust Q2 2026 earnings of $3.33 EPS, beating estimates by 12%, and maintains impressive profitability with 42.92% net income margin and 30.8% ROE. Recent news highlights Moomoo's expansion initiatives and ongoing securities class action lawsuits with August 2026 deadlines.
Wall Street analysts project 33.7% upside potential with 58% buy ratings, but technical indicators and legal risks warrant caution. The stock presents value at 10.86 P/E ratio with strong cash flow generation, though bearish momentum and regulatory scrutiny may pressure near-term performance.
GSK trades at $46.54, down 1.02% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.36 exceeding the $1.27 estimate. Fundamentals show robust profitability with a 72.73% gross margin and 14.52% net margin, while valuation metrics like a P/E of 14.89 appear reasonable. Recent news highlights pipeline advancements, including a $750 million cancer therapy deal and strategic focus on oncology and cost savings.
The outlook is mixed; analyst consensus leans Hold (55.18%) with a minority Buy rating (31.03%), reflecting caution amid an approaching HIV patent cliff. Near-term support is at $45, with resistance at $47. Revenue growth to $33.2B in 2026 and a dividend of $0.45 per share offer stability, but execution risks and competitive pressures remain key watchpoints for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Futu Holdings Ltd
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
